Veterinary Clinical Reference
Look up any drug or condition.
Evergreen, evidence-based hubs on the drugs, conditions, and species you manage — continuously updated and cited at every claim.
Zonisamide for Canine Idiopathic Epilepsy: Efficacy, Tolerability, and Therapeutic Drug Monitoring
Evidence review for veterinarians: a 207-dog TDM cohort proposes a 10-55 mcg/mL canine reference interval and 76% of newly-diagnosed dogs reached >=50% seizure reduction on monotherapy, with feline tolerability signals from a 57-cat cohort.
Read →Enflicoxib (Daxocox) for Canine Osteoarthritis: A Once-Weekly COX-2 Selective NSAID
Enflicoxib (Daxocox) is an EU-authorised, once-weekly COX-2 selective NSAID for canine osteoarthritis. This hub reviews its mechanism, 6-month field efficacy and safety (Salichs 2024), long-term durability, comparators, and clinical placement.
Read →Lokivetmab (Cytopoint) for Canine Atopic Dermatitis: IL-31 Targeting and Clinical Evidence
Lokivetmab (Cytopoint) neutralizes IL-31 to control pruritus in canine atopic dermatitis. Evergreen review of pivotal RCTs, 12-month durability, ciclosporin comparison, COLT combination therapy, and the 2024-2025 JAK-inhibitor landscape.
Read →Robenacoxib (Onsior) for Pain in Cats and Dogs: COX-2 Selectivity and Clinical Evidence
Robenacoxib (Onsior) is a COX-2-selective NSAID with tissue-preferential distribution. Evidence from a feline DJD RCT and perioperative comparison data reviewed.
Read →Potassium Bromide (KBroVet) for Canine Idiopathic Epilepsy: FDA Full Approval, Dosing, and Monitoring
KBroVet (potassium bromide) received FDA full approval in January 2026 for canine idiopathic epilepsy. A clinical reference on mechanism, dosing, pharmacokinetics, bromism, and the real-world serum-monitoring gap (31.6% for bromide vs 77.5% for phenobarbital).
Read →Fluralaner (Bravecto) for Canine Generalized Demodicosis: Field Study Evidence
Two controlled studies confirm 98–100% mite-free rates with a single fluralaner administration for canine generalized demodicosis, outperforming imidacloprid/moxidectin — with 2026 data extending single-dose cure to sarcoptic mange and reviews refining the isoxazoline MDR1 neurologic-safety signal.
Read →Rapamycin (Sirolimus) for Feline Hypertrophic Cardiomyopathy: RAPACAT Trial, Evidence, and Safety
The RAPACAT RCT showed low-dose delayed-release rapamycin significantly reduced LV wall-thickness progression in subclinical feline HCM at Day 180 (P=0.01), with mechanistic and ex vivo platelet-safety data now folded into one evergreen clinical reference.
Read →Cyclosporine (Atopica for Cats) for Feline Allergic Dermatitis: Efficacy and Safety
Atopica for Cats produced a 65.1% lesion score reduction vs 9.2% in controls in a 181-cat field study. FDA-indicated for miliary dermatitis, eosinophilic plaques, excoriations, and self-induced alopecia.
Read →Trilostane (Vetoryl) for Canine Hyperadrenocorticism: Evidence and Monitoring
Trilostane (Vetoryl) inhibits 3β-HSD for canine hyperadrenocorticism, resolving PU/PD in 70% and skin changes in 62% of dogs. Emerging evidence favours pre-trilostane cortisol over the ACTH stimulation test for monitoring clinical control.
Read →Cyclosporine (Atopica) for Canine Atopic Dermatitis: Evidence and Use
Evidence-based guide to cyclosporine (Atopica/Cyclavance) for canine atopic dermatitis: RCT efficacy vs placebo and methylprednisolone, the ~4-week onset and prednisolone bridging strategy, long-term safety, vaccination planning, CYP3A4 interactions, and feline PK contrast.
Read →Imepitoin (Pexion) for Canine Idiopathic Epilepsy: Evidence Review
Evidence-based review of imepitoin (Pexion) for canine idiopathic epilepsy — pivotal RCT efficacy, its favourable adverse-event profile versus phenobarbital, PK, and the emerging off-label feline data.
Read →Maropitant (Cerenia) for Vomiting in Dogs and Cats: Clinical Evidence
Evidence-based review of maropitant (Cerenia) for vomiting in dogs and cats — canine motion sickness, feline CKD, dexmedetomidine-induced emesis comparators, and the emerging visceral-analgesia role — with NK1 mechanism and FDA label facts.
Read →